Drug ‘breakthrough’ gives longest-ever survival in non-resectable liver cancer patients
The IMbrave150 trial found median overall survival was 19.2 months in patients treated with atezo…
Browsing: Atezo bev
New data on emerging treatments for liver cancer raise hope for advanced disease patients
New treatment options for people with advanced or unresectable hepatocellular carcinoma (HCC) may now be…